Clinical Studies Show Efficacy And Safety Of Norwood Abbey Limited Eyecare Epikeratome
10/19/2005 5:13:13 PM
MELBOURNE, Australia--(BUSINESS WIRE)--April 18, 2005--Norwood Abbey Limited (OTC:NABYF) (ASX:NAL):
-- Study in short-sighted patients shows Epi-LASIK is a safe and effective treatment
-- Greater return of corneal sensitivity with Epi-LASIK procedure than with LASIK
-- Study results presented at major U.S. Ophthalmology conference
Norwood Abbey Limited (OTC:NABYF) (ASX:NAL) subsidiary, Norwood EyeCare, the innovative ophthalmic devices company announced results of three clinical studies this week at the American Society of Cataract and Refractive Surgery (ASCRS) meeting, held April 15-20 at the Washington Convention Center (Washington, D.C). All three studies employed Norwood EyeCare's Epikeratome for Epi-LASIK. The study results -- including the evaluation of visual acuity, pain, haze and corneal sensitivity -- suggest that Epi-LASIK with the Norwood EyeCare Epikeratome is a safe and effective modality for the treatment of low and moderate myopia (short-sightedness), based on a one-year follow up.
comments powered by